SCHEMBL23014334

SCHEMBL23014334

CN(C)c1ccc(C(=O)CNC(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.67
POLB P06746 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
FLT1 P17948 1/20 0.56
FLT4 P35916 1/20 0.56
KDR P35968 1/20 0.56
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 3/20 0.53
MAPT P10636 3/20 0.53
UTS2R Q9UKP6 1/20 0.52
HTT P42858 2/20 0.51
MEN1 O00255 2/20 0.51
HDAC1 Q13547 7/20 0.50
HDAC6 Q9UBN7 7/20 0.50
HDAC10 Q969S8 5/20 0.50
HDAC8 Q9BY41 4/20 0.50
HDAC2 Q92769 3/20 0.50
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23014365 0.88 ALDH1A1 (0.51) ALDH1A1POLBTDP1FLT1FLT4
SCHEMBL6200322 0.87 MEN1 (0.62) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL12634168 0.86 ALDH1A1 (0.52) ALDH1A1POLBTDP1KDM4EHTT
SCHEMBL12633570 0.85 ALDH1A1 (0.51) ALDH1A1POLBTDP1KMT2AKDM4E
SCHEMBL23014292 0.85 KMT2A (0.56) ALDH1A1POLBTDP1KMT2AKDM4E
SCHEMBL23014126 0.85 GRM5 (0.56) ALDH1A1POLBTDP1KMT2AKDM4E
SCHEMBL23014091 0.82 LSS (0.52) ALDH1A1KDM4EHTTHDAC1HDAC6
SCHEMBL23014158 0.82 MAPT (0.58) ALDH1A1TDP1KMT2AKDM4EMAPT
SCHEMBL23014128 0.81 ALDH1A1 (0.45) ALDH1A1POLBTDP1KDM4EMAPT
SCHEMBL23014479 0.81 KMT2A (0.73) ALDH1A1KMT2AMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021034087-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND 주식회사 셀젠텍 2021-02-25 WO claimed
US-20230150924-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND CELLGENTEK CO., LTD. (KR) 2023-05-18 US disclosed
EP-4019495-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND Cellgentek Co., Ltd (KR) 2022-06-29 EP disclosed
WO-2021034087-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND 주식회사 셀젠텍 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150924-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND KNTC1, MED1, LEF1 ALDH1A1 1404/4885POLB 1305/4885TDP1 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.